LT3914617T - Antikūnų prieš c5 dozavimas ir vartojimas gydant atipinį hemolizinį ureminį sindromą (ahus) - Google Patents

Antikūnų prieš c5 dozavimas ir vartojimas gydant atipinį hemolizinį ureminį sindromą (ahus)

Info

Publication number
LT3914617T
LT3914617T LTEPPCT/US2020/014998T LTUS2020014998T LT3914617T LT 3914617 T LT3914617 T LT 3914617T LT US2020014998 T LTUS2020014998 T LT US2020014998T LT 3914617 T LT3914617 T LT 3914617T
Authority
LT
Lithuania
Prior art keywords
ahus
antibodies
dosage
treatment
uremic syndrome
Prior art date
Application number
LTEPPCT/US2020/014998T
Other languages
English (en)
Lithuanian (lt)
Inventor
Lori PAYTON
Christian MIX
Rajendra Pradhan
Andrew Damokosh
Eugene Scott SWENSON
Xiang Gao
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of LT3914617T publication Critical patent/LT3914617T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
LTEPPCT/US2020/014998T 2019-01-25 2020-01-24 Antikūnų prieš c5 dozavimas ir vartojimas gydant atipinį hemolizinį ureminį sindromą (ahus) LT3914617T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962796953P 2019-01-25 2019-01-25
PCT/US2020/014998 WO2020154626A1 (en) 2019-01-25 2020-01-24 Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus)

Publications (1)

Publication Number Publication Date
LT3914617T true LT3914617T (lt) 2024-05-27

Family

ID=69740563

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2020/014998T LT3914617T (lt) 2019-01-25 2020-01-24 Antikūnų prieš c5 dozavimas ir vartojimas gydant atipinį hemolizinį ureminį sindromą (ahus)

Country Status (18)

Country Link
US (1) US20220235121A1 (cg-RX-API-DMAC7.html)
EP (1) EP3914617B1 (cg-RX-API-DMAC7.html)
JP (2) JP7511566B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250016490A (cg-RX-API-DMAC7.html)
CN (2) CN113614105A (cg-RX-API-DMAC7.html)
AU (3) AU2020213121A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021014472A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127797A1 (cg-RX-API-DMAC7.html)
DK (1) DK3914617T3 (cg-RX-API-DMAC7.html)
ES (1) ES2980453T3 (cg-RX-API-DMAC7.html)
FI (1) FI3914617T3 (cg-RX-API-DMAC7.html)
HU (1) HUE067202T2 (cg-RX-API-DMAC7.html)
LT (1) LT3914617T (cg-RX-API-DMAC7.html)
MX (1) MX2021008919A (cg-RX-API-DMAC7.html)
PL (1) PL3914617T3 (cg-RX-API-DMAC7.html)
PT (1) PT3914617T (cg-RX-API-DMAC7.html)
SI (1) SI3914617T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020154626A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
JP7518764B2 (ja) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ, インコーポレイテッド 抗c5抗体の産生方法
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下(sc)施用抗c5抗体治疗补体相关病症
CA3173016A1 (en) * 2021-01-22 2022-07-28 Gin-Fu CHEN Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
WO2022234541A1 (en) * 2021-05-07 2022-11-10 Novartis Ag Iptacopan for the treatment of atypical hemolytic uremic syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
JP5878270B2 (ja) 2012-12-19 2016-03-08 プロメラス, エルエルシー 高純度ノルボルネンアルカノールおよびその誘導体の製造方法
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
US20190023775A1 (en) * 2016-01-11 2019-01-24 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
ES2965486T3 (es) * 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
JP7518764B2 (ja) * 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
EP3802603A1 (en) * 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients

Also Published As

Publication number Publication date
FI3914617T3 (fi) 2024-05-24
EP3914617A1 (en) 2021-12-01
WO2020154626A1 (en) 2020-07-30
CA3127797A1 (en) 2020-07-30
MX2021008919A (es) 2021-11-04
JP7511566B2 (ja) 2024-07-05
PL3914617T3 (pl) 2024-08-05
AU2020213121A1 (en) 2021-08-12
AU2024266818B2 (en) 2026-02-19
BR112021014472A2 (pt) 2021-09-21
HUE067202T2 (hu) 2024-10-28
PT3914617T (pt) 2024-05-31
KR20250016490A (ko) 2025-02-03
ES2980453T3 (es) 2024-10-01
AU2026200805A1 (en) 2026-02-26
JP2022518507A (ja) 2022-03-15
DK3914617T3 (da) 2024-05-27
EP3914617B1 (en) 2024-03-13
US20220235121A1 (en) 2022-07-28
KR20210119420A (ko) 2021-10-05
CN113614105A (zh) 2021-11-05
JP7823117B2 (ja) 2026-03-03
SI3914617T1 (sl) 2024-06-28
AU2024266818A1 (en) 2025-01-02
CN117838856A (zh) 2024-04-09
JP2024120942A (ja) 2024-09-05

Similar Documents

Publication Publication Date Title
IL289975A (en) Use of cannabidiol in the treatment of dravet syndrome
DK3914617T3 (da) Dosering og administration af anti-c5-antistoffer til behandling af atypisk hæmolytisk uræmisk syndrom (ahus)
CO2020004838A2 (es) Dosis y administración de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxística nocturna (hpn) y el síndrome hemolítico urémico atípico (shua)
IL284369A (en) Antibody against human il-4ra and use thereof
IL280483A (en) Muscle targeting complexes and uses thereof for treating pompe disease
LT3908270T (lt) Bupropiono ir dekstrometorfano derinys, skirtas azijiečių kilmės pacientų depresijos gydymui
EP3622407A4 (en) SYSTEMS AND PROCEDURES FOR PATIENT TREATMENT
WO2017123636A8 (en) Dosage and administration of anti-c5 antibodies for treatment
IL283200A (en) Combination treatment of nafld and nash
PL3808774T3 (pl) Przeciwciało wiążące ludzki il-4r, jego fragment wiążący antygen i ich zastosowanie medyczne
SMT202600202T1 (it) Regime di dosaggio dividofludimus per l'uso nel trattamento di malattie infiammatorie e/o autoimmunicroniche
IL290256A (en) Anti-pd-1 antibody and pharmaceutical use thereof
LT3774897T (lt) Pacientų, sergančių uždegiminėmis ligomis, atrankos ir gydymo būdai bei sistemos
DK3773689T5 (da) Antigene peptider til forebyggelse og behandling af kræft
IL281900A (en) Design and noise based care areas
IL281990A (en) Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
MA50358A (fr) Sémaglutide en thérapie médicale
IL283518A (en) Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
IL290130A (en) Treatment of immune evasive tumors
HUE060322T2 (hu) Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra
PL3600415T3 (pl) Przeciwciało przeciwko receptorowi aktywiny typu II do stosowania w leczeniu niewydolności serca
EP4041064A4 (en) A medical therapeutic device
HRP20260324T1 (hr) Guselkumab za upotrebu u liječenju crohnove bolesti uz režim doziranja
EP3585442C0 (en) SMALL CELL LUNG CANCER THERAPY (SCLC) WITH AN ANTIBODY-DRUG CONJUGATE (ADC) TOPOISOMERASE I INHIBITOR TARGETING TROP-2
IL281608A (en) Anti-human cd45rc antibodies and uses thereof